A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
News Medtronic wins FDA approval for urinary incontinence deviceHealthradar22. September 2025 Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:…
